NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the way for FDA discussions on [...]
NEW YORK, Jan. 30, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientific Advisory Board. Dr. Rosenstock [...]
Protease inhibitor is a key component of platform technology that protects therapeutic proteins in the digestive system NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery [...]
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board. Dr. Fleming is Founder and Executive [...]
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board. Dr. Skyler [...]
NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a [...]
Dr. Mayer is the current Managing Director and Chairman of the Board of Merck Life Science Israel NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]
NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South [...]
NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and [...]
ORMD-0801 dosed once daily reduced A1C by 0.60% compared to only a 0.06% reduction by placebo ORMD-0801 improves metabolic control as evidenced by significant reduction in A1C levels in patients with type 2 diabetes inadequately controlled on multiple other standard of care drugs NEW YORK, [...]